drugset / Trial / NCT01925911
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
NaSingle-groupOpen-labelBasic science
Summary
To evaluate the effect of IPI-145 on the pharmacokinetics of midazolam, a cytochrome P450 3A (CYP3A) substrate; to assess the safety and tolerability of IPI-145 when administered with midazolam in healthy subjects.
Timeline
- Start
- 2013-08
- Primary completion
- 2013-09
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | 25 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
Indications
No indication recorded.